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Abstract
The functional gastrointestinal disorders (FGIDs) often show inadequate response to usual medical
care. Psychological treatments can help improve FGID patient outcomes, and such treatment
should be considered for patients who have moderate or severe symptoms after 3 to 6 months of
medical care, and those whose symptoms are clearly exacerbated by stress or emotional
symptoms. Effective psychological treatments, based on multiple randomized controlled trials,
include cognitive behavioral therapy (CBT) and hypnosis for irritable bowel syndrome and
pediatric functional abdominal pain; CBT for functional chest pain; and biofeedback for
dyssynergic constipation in adults. Successful referral by the gastroenterologist for psychological
treatment is facilitated by educating the patient about the rationale for such treatment, reassurance
about the diagnosis and continuation of medical care, firm doctor-patient therapeutic alliance, and
identification of, and communication with, an appropriate psychological services provider.
The functional gastrointestinal disorders (FGIDs) are a group of more than twenty chronic
medical conditions of the GI tract that constitute a large proportion of the presenting
problems seen in clinical gastroenterology and are hard to treat effectively. For example, in
a survey of 1,658 patients with FGIDs in a Health Maintenance Organization in Seattle1 the
proportion of patients who reported that their bowel symptoms were at least somewhat better
after 6 months of usual medical management was only 49% for IBS, 63% for functional
diarrhea, and 56% for functional constipation and functional abdominal pain. There is a
clear need for supplemental interventions that can help reduce the morbidity, life impairment
and chronically high healthcare utilization of the many FGID patients who remain highly
symptomatic in spite of all that usual medical care approaches can offer. Psychological
treatments have shown the best overall promise for that purpose to date, and are gradually
becoming widely accepted and recommended options for FGIDs. For example,
psychological treatments are given a “strong recommendation” rating for improving global
IBS morbidity in the current evidence-based position statement of the American College of
Gastroenterology2. Similarly, the AGA technical review on IBS recommends psychological
treatment for moderate and severe patients, those with inadequate response to standard
medical care and patients where psychosocial factors clearly exacerbate symptoms3.
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The rationale for using psychological interventions for FGIDs can be summarized as
follows:
1. Stressful life events trigger exacerbations of symptoms in many patients4 and
traumatic life events such as sexual or physical abuse5 are associated with an
increased prevalence of IBS and other FGIDs.
2. Co-morbid psychiatric disorders such as generalized anxiety disorder and major
depression are highly prevalent in FGID patients (for example, found in 50–94% of
clinical samples of IBS patients6) and anxiety and depression have been identified
as associated with poorer outcomes for FGID patients.7–9
3. The brain exerts a powerful influence over gastrointestinal pain perception, motility
and secretion. In functional dyspepsia, anxiety is correlated with lowered threshold
for gastric discomfort/pain and reduced gastric accommodation10, and depression is
associated with increased postprandial distress, nausea, and vomiting11. In IBS
patients, stress lowers visceral pain thresholds and stimulates colonic and ileal
motility4, 12.
4. Psychological treatments work: A large number of randomized controlled trials
show that short courses of certain psychological interventions can markedly
improve the symptoms of several FGIDs while simultaneously enhancing
emotional well-being and quality of life and sometimes reducing healthcare needs
as well.
The dilemma of the clinical gastroenterologist is that he or she may be convinced that
psychological treatment could help FGID patients but may not know which of the many
forms of such therapies is suitable for a given disorder or how to go about making the
referral. The aims of this article are to make this process easier by (1) identifying and
describing the forms of psychological treatment that show evidence of effectiveness in
FGIDs, (2) summarizing the empirical evidence for their effectiveness, (3) explaining how
to find a suitable local provider, (4) characterizing which FGID patients should be
considered for referral, and (5) describing how to make an effective referral.
Empirically tested psychological treatments for FGIDs
A number of different psychological therapies have been tested for FGIDs in the past 30
years. However, only five modes of treatment have been assessed in multiple randomized
controlled trials (RCTs). That is a necessary standard of evidence for any firm conclusions
to be made about the value of interventions for FGIDs for multiple reasons: Without
randomization, selection bias is likely to confound treatment outcomes; placebo rates are
often high for psychological interventions so placebo control or credible active treatments
are necessary for outcome comparisons; and psychological treatments are generally carried
out within the context of continued medical care, so observed therapeutic responses cannot
be conclusively attributed to psychological treatment without control groups.
Although numerous systematic reviews have been published in the past on psychological
treatments for various FGIDs, these are outdated. Some of the most important and strongest
trials have appeared in the literature only after key reviews were published. We therefore
searched the research literature via Medline (1965–2012) for all RCTs on psychological
treatments for FGIDs (using terms for various common psychological treatments and the
individual FGIDs), and reviewed papers cited in past systematic reviews as well as the
reference sections of the papers found in our online search. Five psychological therapies –
cognitive behavior therapy, hypnosis, psychodynamic interpersonal therapy, relaxation
training, and biofeedback – have been tested in multiple RCTs (see supplemental tables 1–
5), and our review will be limited to those five therapies. As gastroenterologists may not
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have detailed knowledge of the nature of those therapies, we will describe each of them and
then summarize the evidence for their value in FGID treatment. We will exclude from this
overview several studies that combined multiple different psychological treatments –
sometimes as many as four or more different interventions applied simultaneously -- as this
makes it impossible to judge the value of a particular therapy approach.
Cognitive Behavioral Therapy (CBT)
This is a structured form of psychotherapy that is usually conducted individually but can be
administered in group format. The treatment usually consists of a course of 6–12 sessions
that focus on the present situations in which symptoms occur rather than the patient’s past
history. CBT is based on the theory that maladaptive thoughts are the causes of
psychological symptoms such as anxiety and depression, which in turn cause or exacerbate
physical symptoms. An example would be a patient who believes that eating in a public
place will always cause them to have diarrhea and other embarrassing symptoms (a
catastrophizing maladaptive thought), which might lead the patient to both avoid social
interactions (self-defeating behavior) and to become anxious when dining in a restaurant.
The anxiety and autonomic arousal caused by this maladaptive thought may actually trigger
diarrhea. The therapist aims to help the patient recognize maladaptive thoughts and self-
defeating behavior patterns that are adversely affecting life functioning, symptom
experience and mental well-being. Therapy tasks commonly include increasing awareness of
the association between stressors, thoughts, and symptoms; examining and correcting
irrational beliefs; countering automatic negative thoughts; observing and problem-solving
factors that exacerbate symptoms; and identifying and adopting alternative, more effective
coping strategies to handle challenging life situations and deal with gastrointestinal
symptoms. In between therapy visits, patients are typically asked to complete homework
assignments related to the treatment tasks. It should be noted here that the relative emphasis
on individual treatment components varies a lot. Some interventions that fall under the
general umbrella of CBT are mostly or exclusively either cognitive or behavioral in nature:
i.e., they either focus on changing thought patterns or on learning and practicing healthy
behavior patterns.
CBT has been studied more than any other form of psychological intervention for FGIDs in
randomized controlled trials. Thirty RCTs have been published (Supplemental Table 1)
comparing CBT to other interventions. The majority of these trials (18 studies) were
conducted on adults with IBS. Outcomes for CBT treatment were compared to control
groups receiving usual medical care or on waiting lists for the treatment, antidepressant or
antispasmodic medication, placebo or active psychological interventions such as supportive
therapy, education, or stress management/stress reduction treatment. This substantial body
of empirical studies shows that CBT is an effective therapy for improving IBS. In all but
three trials, the CBT arms showed superior outcomes. In the positive trials, gastrointestinal
symptoms were almost uniformly found to be significantly reduced after treatment,
sometimes substantially more than in comparison groups. For example, Payne and
Blanchard13 randomized 34 patients to either 8 weeks of cognitive therapy, a self-help
support group (which controlled for “placebo” or expectancy effects), or a waiting list
group. Cognitive therapy patients showed an average of 67% reduction in the composite
bowel symptom score after treatment, compared to 31% reduction in the support group and
only 10% in the waiting list subjects. Improvement was fully maintained at 3-month follow-
up. While most studies have not included follow-up longer than 3 months post-treatment,
there is evidence that therapeutic benefit of CBT for IBS can last 8 months to 2 years after
treatment termination14–16. In addition to GI symptom improvement, quality of life and
emotional well-being are often documented to improve significantly from such treatment as
well.
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CBT has also proven to be a reliably effective therapy for the treatment of functional chest
pain and recurrent abdominal pain in children (Supplemental Table 1), both of which are
conditions for which no good pharmacologic therapy exists.
Five RCTs on non-cardiac chest pain all found superior outcomes for patients assigned to
CBT compared to control groups, with four of them showing the treatment to be effective in
reducing the pain problem 17–20 and the fifth (which used the shortest course of treatment –
only 3 sessions) finding only an effect on quality of life21. Especially noteworthy is the
study by Spinhoven and colleagues20, who assigned 69 patients to either CBT, paroxetine or
usual medical care. The CBT patients had a greater reduction in pain than both the
medication and usual care groups, and only the CBT group showed reduction in heart-
focused anxiety after treatment (even though paroxetine is often used to treat anxiety
problems). Six RCTs have tested CBT for recurrent abdominal pain in children. In such
treatment, parents and children are commonly both treated together. Here again, all the trials
have found CBT to lead to better outcomes (diminished pain), with CBT generally leading
to longer term pain reduction and higher rates of elimination of pain compared to control
groups.
A noteworthy recent development in the field of CBT for FGIDs is testing of mostly or
entirely self-administered CBT, with minimal involvement of clinicians or staff. The
internet, printed manuals, or PDAs serve as the principal mode of therapy delivery, and this
addresses the important limitation of lack of CBT therapists in many geographical areas.
Seven such randomized trials (identified with an asterisk in supplemental Table 1) have been
reported so far, mostly in IBS treatment. All of them show that this method of delivering
CBT leads to superior outcomes compared to the control conditions. Moreover, the largest
randomized-controlled trial ever conducted on psychological treatment for functional
gastrointestinal disorder, a multicenter NIH-funded trial with estimated enrollment of 480
IBS subjects22, is currently evaluating the potential of self-administered CBT further. Even
though such cost-effective therapy is not yet generally available, the consistently positive
findings to date suggest that a very inexpensive and easily accessible form of effective CBT
may be on the horizon for IBS and perhaps other FGIDs.
Hypnosis treatment
Clinical hypnosis is a verbal intervention that utilizes a special mental state of enhanced
receptivity to suggestion to facilitate therapeutic psychological and physiological changes.
Treatment sessions, which are generally conducted one-on-one, begin with an induction of
the hypnotic state. This is accomplished in various ways that generally involve relaxation,
narrowing and intensification of the focus of attention (for example, by means of eye
fixation), and the patients’ gradual release of deliberate control of their mental activity. Once
the hypnotic state has been achieved, deepening of the altered state generally follows with
the aid of counting, physical relaxation and guided mental dissociation from the here-and-
now. The hypnotherapist then conducts the clinical intervention, which is composed of
targeted verbal suggestions and therapeutic imagery to encourage improvement in
symptoms. In the treatment of FGIDs, imagery and suggestions commonly aim at regulating
smooth muscle activity, reducing the impact of stress on GI symptoms, reducing gut pain
perception and attention to symptoms, and increasing the patient’s sense of control over
symptoms. Examples of imagery used in IBS hypnosis treatment are a mental image of the
intestinal wall being coated with a strong protective coating that makes it immune to
irritation or pain, or imagining the bowel as a river and the patient mentally slowing or
speeding the flow of the river to counter diarrhea or constipation. Similar to CBT, hypnosis
treatment for FGIDs usually consists of a course of 6–12 therapy sessions, and patients are
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commonly asked to practice hypnosis at home in between visits with the aid of audio
recordings.
Hypnosis treatment has been tested for FGDs in 11 published RCTs to date (Supplemental
Table 2). Control groups have included supportive talk therapy, placebo pills, waiting lists,
multi-component (non-hypnotic) audio recordings, and usual medical care. Seven of these
trials were on IBS in adults, and all except one of those RCTs found hypnosis to result in
significantly greater improvement in gastrointestinal symptoms than seen in the comparison
groups. Emotional symptoms and quality of life also improved significantly in studies where
these parameters were measured. Improvement from hypnosis treatment generally lasts a
long time. Two of the RCTs reported therapeutic gains in treatment responders to be fully
maintained at 1023 and 1824 months after treatment, respectively. Separately, one of the
investigative teams published a large case series of 204 consecutive IBS patients whose
symptoms were reassessed annually for years after hypnotherapy, and reported that 81% of
patients maintained their treatment gains fully for at least 5 years25. Overall, the data
strongly indicate that hypnosis treatment is an effective intervention for IBS.
Two controlled studies have investigated the impact of hypnosis treatment on pediatric
abdominal pain, both with impressive results. Vlieger and colleagues in the Netherlands
randomly assigned 53 children with functional abdominal pain to either 6 sessions of
hypnotherapy or supportive therapy26. The pain improved far more in the hypnosis group,
and at 1 year follow-up, 85% of the hypnosis subjects and 25% of controls were treatment
responders. At five-year follow-up, the pain of a significantly higher proportion of the
hypnosis subjects than controls was in remission (68% vs. 20%)27. In the second study,
conducted in the U.S. by our research team28, children were randomized to either guided
imagery treatment (a variant of hypnosis that used hypnotic suggestions and vivid imagery
without formal hypnotic induction) or usual medical care. The hypnosis intervention was
self-administered by the children at home via audio recordings. At the end of treatment, pain
was reduced by half or more compared to pre-treatment assessment in 73.3% of the hypnosis
group versus only 26.6% of the usual medical care group. Although it is desirable for more
studies to be conducted on this application of hypnosis, this pair of trials indicates that
hypnosis is a good option for reducing pediatric abdominal pain.
Finally, two initial randomized placebo-controlled investigations have found hypnosis
treatment to lead to dramatically greater immediate and long-term improvement in the
symptoms of non-cardiac chest pain29, 30 and functional dyspepsia31 compared to supportive
talk therapy, placebo pills, and - in the functional dyspepsia trial - compared to ranitidine as
well. These FGIDs therefore appear to be promising new targets for hypnosis intervention,
but further empirical work is needed to evaluate those applications of this therapy.
Relaxation training
This category of psychological treatment describes a heterogeneous group of interventions
that principally aim to reduce sympathetic nervous system arousal and lessen physiological
stress reactivity. Relaxation training is often included as a component of other interventions
(such as CBT) and has also been used as control treatment for other psychological treatment.
However, we identified 7 randomized studies where such treatment was tested as a
monotherapy for FGDs, all of them in IBS (supplemental table 3). One sizable trial, by
Boyce and colleagues, compared outcomes for relaxation training with those of cognitive-
therapy and standard medical care and found no outcome differences between the treatment
arms32. In contrast, the other 6 RCT all found some significant benefits of relaxation
training not seen in the comparison groups. Therefore it seems that interventions that aim at
reducing autonomic arousal and stress reactivity are helpful in IBS. As few as 5 sessions are
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needed33. However, the treatment methods tested in this group of studies have been so
varied that they could be considered different forms of treatment. Only progressive
relaxation has been tested in more than one of the positive trials. This is a form of
physiological relaxation achieved by systematically alternating tensing and relaxing muscles
in different muscle groups of the body, and noticing the contrast between the feeling of
tension and relaxation. Over time, patients learn in this way to more effectively release
muscle tension and relax their body more thoroughly.
Psychodynamic therapy
Psychodynamic therapy and interpersonal therapy (a less common variant of psychodynamic
therapy focused on interpersonal relationships) are insight-oriented therapies that aim at
reducing symptoms through gaining an understanding of unconscious processes that may be
responsible for those symptoms. Both psychodynamic therapy and interpersonal therapy
were reported to improve IBS symptoms in early randomized controlled trials (supplemental
Table 4), but the largest and most rigorous RCT of interpersonal therapy for IBS, by Creed
and colleagues34 failed to show any advantage over standard medical care. Based on this
mixed experience and the lack of therapists offering interpersonal therapy, the only type of
psychodynamic therapy tested in multiple RCTs for FGIDs, psychodynamic treatment is not
considered a generally useful option for FGID patients.
Biofeedback
Biofeedback is a form of behavioral training that uses continuous visual or auditory
feedback from recordings of specific physiological activity to enable patients to learn to
voluntarily control those body functions. For example, in a patient who is constipated
because she paradoxically contracts her pelvic floor muscles when having a bowel
movement, the electromyographic (EMG) activity of her pelvic floor muscles might be
shown as a dynamic graph on a computer screen while she simulates defecation to help
teach her how to relax the pelvic floor muscles instead of contracting them. The therapist
would provide verbal instructions and encouragement during her attempts to relax the
muscles. In a patient with fecal incontinence, on the other hand, biofeedback might be used
to teach patients how to more effectively contract an external anal sphincter that is very
weak due to an obstetrical injury or other causes; in this case biofeedback would be used to
teach the patients an appropriate pelvic floor muscle exercise to practice at home to
gradually increase the strength of the muscle. Biofeedback can also be used for sensory
training, i.e., to improve the patient’s ability to detect and respond appropriately to
physiological sensations such as stool or gas suddenly filling up the rectum. This type of
training would be used in a patient who is unable to recognize when it is necessary to
contract the pelvic floor muscles to prevent leaking gas or liquid stool because of a nerve
injury. Usually 4–6 training sessions spaced 1–2 weeks apart are used whether the indication
is constipation or fecal incontinence.
Pelvic floor biofeedback as described above is distinctly different from the other forms of
psychological treatment for FGIDs discussed above because it is not used to cause changes
in thoughts or feelings; rather it is utilized to help patients learn to overcome specific
physiological deficits directly. A different type of biofeedback is sometimes used to teach
patients how to relax all the muscles of their body or to reduce autonomic arousal to
counteract stress, but those techniques are very different and rarely used to treat
gastrointestinal disorders.
Biofeedback has been tested in randomized studies (supplemental Table 3) almost
exclusively as a therapy for functional constipation (16 RCTs) and fecal incontinence (9
RCTs). Comparison conditions have varied, including medical management, sham or non-
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anorectal biofeedback, balloon defecation training, polyethylene glycol, behavioral
modification, diazepam, placebo, botox and surgery. Six of 9 RCTs in constipated adults
found biofeedback patients to have significantly better outcomes than control patients (Table
5). Of the three negative studies, one was methodologically flawed as it did not limit
enrollment to patients with evidence of pelvic floor dyssynergia35; it is now evident that
biofeedback does not work for constipation unless patients have dyssynergic defecation36.
The other two negative trials came from a single group of researchers in Egypt37, 38 who
found biofeedback to be less effective compared to botox injection and, in one of the studies,
compared to puborectalis surgery as well. In short, it seems that biofeedback is effective in
adults with dyssynergic functional constipation, although it may possibly not be as effective
as botox injection or surgery. The largest and methodologically strongest trials all show a
clinically significant improvement in constipation that is substantially greater in patients
treated with biofeedback than in control patients (70–86% vs. 22–48%)39–41, and therapeutic
gains are well maintained for at least 1 year after treatment.
In contrast to the predominantly positive studies in adults, only two of 7 published
controlled trials testing biofeedback for constipation in children found an advantage for
biofeedback compared to the control conditions. This unfavorable outcome picture may be
in part due to two of the trials not limiting testing to dyssynergic patients. It has also been
suggested that children may lack the ability to concentrate on the biofeedback task for
sustained period of training42. In any case, based on the available evidence biofeedback
cannot be recommended for treating constipation in children.
Biofeedback has been advocated for the treatment of fecal incontinence since the first case
series was described in 197443. However, as shown in supplemental Table 5, only 3 of 9
RCTs show superior outcomes of biofeedback treatment compared to control conditions.
Both of the 2 trials of biofeedback for encopresis in children yielded negative results44, 45.
The three studies in adults that compared biofeedback to conservative management which
combined pelvic floor exercises with education46–48 likewise found no advantage for
biofeedback, which suggests that biofeedback may not generally help fecal incontinence
patients more than those more widely available interventions for fecal incontinence. Much
better results were found for biofeedback in adults in a study by Heymen and colleagues49,
who only enrolled non-responders to a run-in education and medical management
intervention in a randomized trial of either biofeedback or pelvic floor exercises alone.
Biofeedback showed clear superiority under these circumstances (77% of patients reported
adequate relief versus 48% in the pelvic floor exercise group), and improvements were well
maintained for up to 12 months. These findings suggest that biofeedback is likely to be
useful for improving outcomes for adult fecal incontinence patients who are have not had
satisfactory response to conservative management.
Biofeedback has also been tested for anorectal pain and functional dyspepsia in single
RCTs. In a large trial on 157 individuals with chronic idiopathic anorectal pain50,
biofeedback resulted in much higher rates of pain relief (87%) than were seen for
electrogalvanic stimulation (45%) and levator muscle massage (22%) conditions, and
treatment benefits were maintained at one-year follow-up. Thus, biofeedback holds strong
promise for the future as a possible advancement in the management of this difficult-to-treat
problem. The only trial of biofeedback for functional dyspepsia51 did not report the effect of
this treatment on dyspepsia symptoms (but reported biofeedback to result in greater drinking
capacity and quality of life improvement compared to no treatment) and therefore provided
little direct information about the potential value of this therapy for improving the clinical
symptoms of dyspepsia.
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As the above summary of these five psychological treatments illustrates, a vast amount of
published RCT data support the value of psychological therapies as interventions for FGIDs.
It should be acknowledged that many of the trials in this domain have methodological
shortcomings: The great majority of them have been small; many have used waiting lists or
mere symptom monitoring as control groups, both of which are likely to produce negative
expectation of improvement that may exaggerate outcome contrast with the active treatment.
Therapies are sometimes poorly described, making it hard to know exactly what therapy was
tested or how to replicate it. Results have also been measured in numerous different ways
that make it hard to compare outcomes across trials. Nonetheless, the preponderance of
evidence, buttressed by some methodologically strong trials for each psychological modality
tested, makes a strong case for the psychological treatment as adjunctive therapy options to
consider for FGID patients.
Which patients should receive psychological treatment?
Psychological treatment is neither necessary nor reasonable for most FGID patients. A
substantial proportion, especially those with relatively mild symptoms, gain sufficient
symptom relief from the usual medical care provided in gastroenterology and primary care
practices. The extra healthcare costs and substantial time and effort that psychological
interventions require may not be warranted for those individuals. However, psychological
treatment should in our opinion generally be considered for two types of patients:
1. Patients who continue to have moderate or severe symptoms after 3 to 6 months of
medical management
2. Patients whose case presentation suggests that stress or emotional symptoms are
likely to be exacerbating GI symptoms or impairing coping with illness.
Not all patients within these two categories are equally well suited for referral. Individuals
who do not recognize or are unwilling to accept the role that stress or psychological
symptoms influence the severity of their gastrointestinal symptoms will not be likely to
follow through with such treatment. Patients with disabling psychiatric symptoms or thought
disorder may have difficulty complying with a psychological treatment regimen for FGIDs,
and could require treatment with psychotropic medications prescribed by a psychiatrist.
Patients who are very unmotivated to assume an active role in managing their own health
condition may also do poorly with psychological treatment, which requires considerable
effort and work over a number of sessions with a therapist.
Choosing appropriate psychological treatment
What kind of psychological treatment is selected for each patient will be influenced to some
degree by local availability of the different psychological services, patient preference, and
the clinician’s past experience with referrals for the problems to be addressed. However, the
following general guidelines can be given about the choices that are most likely to yield
good results, based on the literature to date:
a. Psychological treatment to improve gastrointestinal symptoms. If the goal of the
referral is to achieve better improvement in GI symptoms than has been possible
with medical management, cognitive-behavioral therapy and hypnosis offer
excellent chances of improvement in IBS symptoms and pediatric abdominal pain.
Relaxation training (especially progressive muscle relaxation) is also a suitable
option for IBS treatment. Non-cardiac chest pain shows a good response to CBT.
For constipation due to pelvic floor dyssynergia in adults, biofeedback is a good
option. However, slow transit constipation without evidence of dyssynergic
defecation is unresponsive to this therapy. Functional abdominal pain in children
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can be treated effectively with family CBT and hypnosis. There is insufficient
empirical evidence to recommend particular therapies for other FGIDs, but single
sizable and methodologically strong RCTs suggest that biofeedback might be worth
consideration for levator ani syndrome (especially if patients have puborectalis
tenderness on physical examination)50 and hypnosis for functional dyspepsia31.
b. Psychological treatment for co-morbid affective symptoms. If the primary goal of
referral is reduction in co-morbid emotional symptoms such as anxiety or
depression, cognitive-behavioral therapy is generally the best choice, as there is
somewhat better evidence than for other forms of psychotherapy that CBT can
reliably reduce these affective symptoms in a short course of treatment52, 53. CBT
is also particularly well suited for helping patients with maladaptive coping styles,
such as a tendency to catastrophize or excessive pre-occupation with bowel
symptoms, which can impair life functioning and quality of life in FGIDs. If life
stress or stress-related symptoms is thought to be a key problem and the patient is
able to recognize this, relaxation therapies are likely to be well received and
effective. If somatization, i.e. the psychological tendency to experience a multitude
of non-specific body symptoms is a prominent problem, hypnosis treatment may be
a suitable treatment option since it has been more often shown to reduce non-
gastrointestinal symptoms in FGIDs than other therapies23, 54, 55.
How to best ensure effective referral for psychological treatment
Referral of a FGID patient for psychological treatment is often a delicate matter. Patients
generally consult a gastroenterologist with the expectation of being investigated and treated
for organic disease. They may be unaware of the influences of emotions and the brain on
gastrointestinal functioning and may not see psychological treatment as relevant to their GI
problems. Any suggestion of such treatment is easily misunderstood as indicating that their
gut symptoms are a mere psychiatric problem. For good probability of success,
psychological referral therefore requires tact, correct timing, good doctor-patient
communication, ensuring that the patient clearly understands the rationale for referral, and
also considerable effort on the part of the doctor or clinic staff to manage the referral. The
following steps can help to ensure high probability of successful referral:
a. Introduce the role of psychological influences and psychological treatment early
with FGID patients. When a psychological referral is mentioned for the first time
after a course of medical treatment has failed to produce satisfactory results, the
patient is more likely to interpret this as the physician giving up on finding the
cause or treatment for the gastrointestinal symptoms. Conversely, if psychological
treatment has been a part of the picture the patient has of management of the
disorder from the beginning, it may instead seem like the logical next step in
treatment efforts. This early introduction of the brain-gut relationship and
psychological treatment in the disorder can be in the form of a brochure given at
the end of the first visit, as well as incorporated in education of the patient when the
diagnosis is verbally explained.
b. Reassure the patient that the correct diagnosis has been made. Patients who think
that they may have an organic disease and have little confidence in their functional
GI diagnosis are unlikely to be accepting of referral for psychological therapy, as
they are likely to see it as inappropriate and even a reckless distraction from
pursuing the “real” cause of their symptoms. Thorough explanation of the disorder
and the reasons for confidence in the diagnosis, coupled with reassurance that it is
highly unlikely that alternative dangerous medical problems can account for the
symptoms, is advisable before referral for psychological treatment is discussed.
Palsson and Whitehead Page 9













c. Establish a firm therapeutic alliance. If the physician makes clear that he or she is
committed to working with the patient to pursue whatever means are possible to
achieve the best symptom reduction and quality-of-life enhancement, and discusses
the different options for this purpose with the patient as a partner in that endeavor,
this sets the stage for discussing psychological treatment as a logical part of overall
symptom management.
d. Explain thoroughly the rationale for the psychological treatment. As emphasized
by Drossman and colleagues in the AGA technical review on IBS3, explaining to
FGID patients the rationale for referral for psychological treatment is crucial. It
may be the single-most important factor for a referral to work. This explanation
should first of all include why psychological treatment is likely to help. For that
purpose, explanation of the brain-gut axis and the way the brain down-regulates or
amplifies pain perception and gut activity is essential. One should also explain that
this control is tuned by both strong emotions and stress, and that psychological
treatment can use that same mind-body relationship to neutralize symptoms and the
impact of emotions. As the effects of stress and the gut is apparent to the patient
from his or her own experience, examples such as nausea, butterflies in the stomach
or lump in the throat in response to strong emotions can help illustrate this
discussion. Secondly, the fact that numerous studies show that psychological
treatments improve outcomes for patients with FGID compared to medical
treatment alone should be discussed, and especially the evidence for the particular
therapy being proposed.
e. Identify suitable local service providers. There is great advantage to identifying
one or more suitable therapists for referral in the community, and learning which
therapies they can provide that are appropriate for FGIDs, before referral is
discussed with the patient. Relying on the patients’ initiative to find an appropriate
therapist is unlikely to succeed, as their understanding of what is required may be
limited. Taking the trouble to find suitable local therapists and learn about their
services can pay off handsomely, since a good provider can be utilized again and
again for referrals. If the gastroenterologist already knows what type of
psychological treatment will be used and can describe how it works in general
terms, this is more credible to the patient and can facilitate follow-through.
Appropriate therapists are generally clinicians who are experienced in treating
physical health problems, and preferably gastrointestinal disorders, with
psychological methods. In general, mental health providers who list health
psychology or behavioral medicine as their focus of practice are likely candidates
for referral. For finding therapists who provide particular types of psychological
services most suitable for FGIDs, consulting online resources for therapist referrals
can also be helpful. Useful websites for finding therapists in any part of the U.S.
include www.abct.org and academyofct.org for CBT, www.asch.net and
www.ibshypnosis.com for hypnosis, and www.bcia.org for pelvic floor
biofeedback. Physicians practicing in small towns or rural areas may not be able to
find providers of these psychological services locally, but should consider locating
providers in the nearest major urban center, as patients may be willing to travel
some distance for a short course of such specialized treatment.
f. Communicate with the psychological services provider. Many GI patients will not
be able to effectively convey the goals of referral for their FGID problem to the
psychological services provider. It can therefore be greatly advantageous to provide
the patient with a referral letter explaining the rationale and expectations for the
referral. The letter should make clear that what is being sought is a brief course of
adjunctive therapy and it should be clearly stated whether the desired principal goal
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of the referral is to treat affective symptoms or the GI symptoms. It can also be
very helpful to request a written report back from the therapist if treatment does not
seem appropriate or if therapy response is poor, so that other options can be
selected instead, and to encourage the provider to telephone about coordinating
psychological treatment with ongoing medical treatment.
g. Place emphasis on continuation of GI care. Emphasizing both to the patient at
the time of referral and in the referral letter to the therapist that the
gastroenterologist will continue to manage the overall GI care of the patient can
reassure patients who have such anxieties that he or she is not being “dumped” and
give the therapist a better understanding of the context for his or her work with the
patient. Encouraging the patient to schedule a return GI visit at the end of the
course of psychological treatment to assess progress and decide on next steps if
needed will further reinforce this sense of continuation of care and strengthen the
doctor-patient therapeutic alliance.
Psychopharmacologic treatment as an alternative to psychological
treatment
Psychotropic medications, and especially anti-depressant, have been shown to have utility in
the treatment of FGIDs in a number of studies. These medications can sometimes be used to
a significant degree to accomplish the two main tasks that we have described for FGID
psychotherapy in this article: To reduce GI symptom intensity and manage co-morbid
affective symptoms56. Use of antidepressants has become fairly well established for
functional GI symptoms, especially in IBS. At least one in every eight IBS patients is
offered antidepressant medication57. Ford and colleagues recently conducted a systematic
review of both RCTs of antidepressant medication and psychological therapies in IBS, and
concluded that the number needed to treat (NNT) was 4 for both types of intervention58.
Psychotropic medications may therefore be a suitable alternative to psychological treatment
for many patients, and this option has the pronounced advantage of not requiring outside
referral. However, psychotropic drugs also have some limitations relative to psychological
treatments. The medications that have the best evidence of effectiveness in therapeutic value
for FGID symptoms are old-style tricyclic anti-depressants that have relatively unfavorable
side effect profile56. Some of the most common side effects of antidepressants in general are
gastrointestinal symptoms such as nausea and constipation, and the safety of these
medications in patients with gastrointestinal disorders is not well known2. Furthermore,
psychotropic medications can interact with other drugs the patients are taking. Finally,
unlike the effects of psychological treatments, which often last many months or even years
beyond the end of treatment, psychotropic medications need to be administered chronically
for lasting benefit.
Summary and conclusions: Advantages and limitations of psychological
treatment
As our summary of individual treatments above demonstrates, a substantial literature
supports the value of psychological treatment for patients with FGIDs. Good improvement is
often seen from such treatment in patients who have shown little or no response to usual
medical care. These therapies have no adverse side effects and do not cause interactions with
pharmacologic treatment, making them well suited as co-therapies with medical care. Apart
from improvement in symptoms these therapies often bring patients positive outcomes
including better quality of life, enhanced emotional well-being and life functioning,
improved coping with the illness, and lessened healthcare and medication needs. The
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prospects of such improved well-being and functional outcomes are sufficient benefits to
warrant referrals for these therapies for some patients.
There are limitations and challenges to the utilization of psychological treatments in the
FGIDs, however. For good success, referrals for such treatment require good therapeutic
alliance between doctor and patient, reassurance and education. It may be hard to find
therapists in some areas who are skilled in the particular therapy modalities with best
evidence of effectiveness for particular FGIDs. Also, the amount of effort and motivation
required of patients to make use of psychological treatments may make it unsuitable for
some individuals. Insurance reimbursement for psychological therapies for FGIDs is
variable and not available in all insurance plans, so cost may be an obstacle for some
patients.
In addition to these limitations that are common to all the treatment modes, the various
treatments also have different challenges. The idea of hypnosis treatment may cause
wariness in some patients due to the common misconceptions about hypnosis in mass media
and the general culture. Cognitive behavioral therapy generally depends heavily on
homework assignments and therefore requires diligent and self-motivated patients for the
best results. Biofeedback is more invasive than the other forms of psychological treatment,
and some patients may be uncomfortable with use of intra-rectal sensors. Finally, the
research to date has only identified effective psychological treatments for a few of the many
FGIDs. Despite all of these limitations, the current state of knowledge clearly indicates that
psychological treatment should be considered for the subgroup of FGID patients who do not
gain satisfactory symptom relief from usual gastroenterology management, and is likely to
significantly improve their clinical outcomes.
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